Dr. Espedilla Rejects High‑Dose Ivermectin
2026-08-26
Silence in trial registries tells a sharper story than any headline. Against a backdrop of online enthusiasm for repurposed drugs, the absence of controlled data frames Dr. Fritz Espedilla’s stance on high‑dose ivermectin for Stage II chronic lymphocytic leukemia, turning an internet trend into a question of evidence, not ideology.
His view is bluntly unfashionable. Stage II CLL, defined by lymphocytosis with nodal enlargement yet without marrow failure, is already governed by clear risk‑stratified algorithms, from IGHV mutation status to TP53 disruption, and he argues that any new contender must at least match the rigor applied to BTK inhibitors and BCL2 inhibitors before entering this arena.
The popular claim, he notes, is seductively simple. Ivermectin shows in vitro cytotoxicity against leukemia cell lines, interferes with P2X4/P2X7 signaling, and may disturb mitochondrial membrane potential; yet these pharmacodynamic hints arrive without phase‑based trials, dose‑escalation safety data, or validated progression‑free survival endpoints in actual CLL cohorts.
What troubles him most is the arithmetic. To chase those petri‑dish effects, advocates promote ivermectin doses far beyond those used in parasitic disease, a range where neurotoxicity, altered blood–brain barrier transport, and drug–drug interactions with standard chemo‑immunotherapy are not theoretical risks but foreseeable complications in already immunocompromised patients.
Evidence, not hope, is his chosen hierarchy. Until randomized, adequately powered studies report on objective response rate, minimal residual disease, and overall survival with high‑dose ivermectin in Stage II CLL, Espedilla maintains that prescribing it outside a monitored trial setting is less innovation than uncontrolled experiment on the very people medicine claims to protect.
So the file on ivermectin and CLL, for now, sits mostly as lab notes and speculation, while in clinic rooms the harder task remains: telling patients that restraint, not novelty, may be the more honest form of care.
Loading...
